Remibrutinib-GA2LEN Global Urticaria Forum

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the phase 3 studies

A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, S. Saini, S. Haemmerle, N. Seko, P. Wang, M. Maurer, El. D. Martzloff

Poster

Safety and efficacy of remibrutinib in Japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)

K. Hayama, Y. Chinuki, A. Yagami, A. Kume, T. Sasajima, S. Matsushima, K. Lheritier, S. Haemmerle, M. Hide

Oral Presentation

Physician’s perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

J.A. Bernstein, T.A. Winders, J. McCarthy, P. Saraswat, N.C. Rothe, T. Raftery, K. Weller

Poster

Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, P. Staubach, S. Saini, M. Hide, M. Lebwohl, M. Maurer, G. Sussman, S. Haemmerle, K. Lheritier, El. D. Martzloff, A. Zharkov

Poster

CSU disease activity band shift after long-term treatment with remibrutinib in the phase 3 REMIX-1 and REMIX-2 studies

M. Metz, A. M. Giménez-Arnau, P. Staubach, M.F. Puga, K. Kulthanan, X. Gao, K. Lheritier, C.E. Ortmann, N.C. Rothe, S. Haemmerle, A. Fukunaga, M. Hide

Poster

Frequency of angioedema in patients with chronic spontaneous urticaria: Report from the Urticaria Voices study

J.A. Bernstein, T. A. Winders, M.M. Balp, P. Saraswat, J. McCarthy, T. Raftery, M. Kuruvilla, K. Weller

Poster

No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria

G. Sussman, M. Palumbo, S. Gogate, A. Fukunaga, S.F. Thomsen, M. Maurer, A. Burciu, P. Wang

Poster

Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the phase 3 REMIX-1 and REMIX-2 studies

M. Metz, J. Reed, S. Saini, R. Szalewski, M. Lebwohl, M. Maurer, G. Sussman, S. Haemmerle, N. Seko, P. Wang, C. Field, M.J. Palumbo

Poster

Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

A.M. Giménez-Arnau, M. Metz, M. Hide, V. Jain, A. Khemis, M. Lebwohl, M. Palumbo, S. Saini, E. Şavk, G. Sussman, R. Szalewski, I.W. Herniczek, H. Windom, B. Yang, S. Haemmerle, K. Lheritier, P.G.P. Machado, El-D. Martzloff, N. Seko, P. Wang, M. Maurer, A. Zharkov

Poster

REMIX-1/-2: Early symptom improvements with remibrutinib in chronic spontaneous urticaria from week 1

S. Saini, R. Szalewski, X. Gao, S. Altrichter, S. Haemmerle, N. Seko, M. Hide

Poster

Efficacy of remibrutinib on patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies

S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, M. Maurer, M. Metz, G. Mosnaim, G. Sussman, S. Haemmerle, K. Lheritier, El-D. Martzloff, N. Seko, P. Wang, S. Gogate

Poster

Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the phase 3 REMIX-1 and REMIX-2 studies

S. Saini, M. Maurer, F. Berard, J. Reed, S. Altrichter, C.Yu. Chu, B. Suryawanshi, C.E. Ortmann, N.C. Rothe, S. Haemmerle, J. Kern

Poster

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study

Tonya A. Winders, Jonathan A. Bernstein, Maria-Magdalena Balp, Jessica McCarthy, Pedro Laires, Pallavi Saraswat, Tara Raftery, Karsten Weller

Poster

Efficacy and safety of remibrutinib in CSU: REMIX 1&2 Studies

S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, A. Barron, S. Haemmerle,
I. Hampele, K. Lheritier, E-D Martzloff, A. Zharkov, M. Maurer

Oral Presentation

Long-term safety and efficacy of remibrutinib in patients with CSU

A.M. Giménez-Arnau, J. Tillinghast, V. Jain, S. Haemmerle, K. Lheritier P. Walsh, S. Hugot, M. Wells, A. Zharkov, W. Carr

Oral Presentation

Remibrutinib improves hive severity in patients with CSU

M. Maurer, K. Sitz, A.M. Giménez-Arnau, K. Hayama, V. Jain, K. Lheritier, P. Walsh, S. Haemmerle

Poster

Study design of remibrutinib Phase-3b extension trial in CSU patients

M. Hide, M. Maurer, A. M Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, K. Lheritier,
A. Zharkov, L. Wei, E-D. Martzloff, S. Haemmerle

Poster

Remibrutinib achieves early and high response rates in CSU patients

A.M. Giménez-Arnau, M. Maurer, R. Snyder, C-E Ortmann, B. Suryawanshi, I. Nikolaev,
M. Kuruvilla, S. Haemmerle

Poster

Remibrutinib provides fast, clinically important improvement of CSU disease activity

M. Maurer, J. Jacobs, A.M. Giménez-Arnau, S. Savic, C-E. Ortmann, B. Suryawanshi, I. Nikolaev,
S. Haemmerle

Poster

Remibrutinib showed good stability of response in patients with CSU

M. Maurer, J. Tillinghast, V. Jain, A. M. Giménez-Arnau, A. Reich, C-E Ortmann, P. Walsh,
S. Haemmerle

Poster

Remibrutinib improves itch, sleep and activity in patients with CSU

M. Maurer, A.M. Giménez-Arnau, C. Hsu, R. Snyder, L. Clore, V. Jain, K. Lheritier, P. Walsh,
S. Haemmerle, I. Nikolaev

Poster

Remibrutinib showed no impact on blood counts in CSU patients

A.M. Giménez-Arnau, J. Leflein, M. Hide, K. Lheritier, S. Haemmerle, M. Kuruvilla, A. Zharkov

Poster

Remibrutinib showed no impact on serum immunoglobulin in CSU patients

A.M. Giménez-Arnau, W. Carr, K. Lheritier, S. Haemmerle, A. Zharkov, S. Dahale, K. Hayama

Poster

Remibrutinib improves CSU symptoms irrespective of previous anti-IgE treatment

M. Maurer, A. Greiner, S. Guduri, J. Leflein, S. Haemmerle, K. Lheritier, P. Walsh, I. Nikolaev,
A.M, Giménez-Arnau

Poster

Pooled safety analysis of remibrutinib in inflammatory immune-mediated diseases

M. Hide, S. Saini, M. Maurer, A.M. Giménez-Arnau, G. Sussman, S. Haemmerle, N. Barbier,
A. Zharkov

Poster

Remibrutinib improves CSU in patients regardless of prior oral treatments

A.M. Giménez-Arnau, L. Clore, M. Maurer, C-E. Ortmann, B. Suryawanshi, M. Kuruvilla,
S. Haemmerle

Poster

Systemic manifestations during symptomatic episodes in CSU: Urticaria Voices Study

J.A. Bernstein, T.A. Winders, T. Raftery, P. Saraswat, J. McCarthy, M. Kuruvilla, M-M Balp, K. Weller

Poster

Urticaria Voices: Patient-reported outcome measures for monitoring CSU in clinic

J.A. Bernstein, P. Laires, M-M. Balp, P. Saraswat, T. Raftery, J. McCarthy, M. Dricu, T.A. Winders,
K. Weller

Poster

Antihistamine treatment patterns and patient reported control In CSU

K. Weller, J.A Bernstein, M-M. Balp, J. McCarthy, M. Kuruvilla, P. Saraswat, T. Raftery, T.A. Winders

Poster

Patients’ perspective on negative impact of CSU on their lives

K. Weller, P. Laires, M-M Balp, T. Raftery, P. Saraswat, J. McCarthy, M. Dricu, T.A. Winders,
J.A. Bernstein

Poster

Remission and relapse profiles in chronic urticaria: PREDICT-CU study

A. Marsland, M-M.Balp, I. Pivneva, A. Danyliv, K. Chen, T. Cornwall, J. Signorovitch, D. Patil,
R. Kohli, T. Severin, W. Soong

Poster

December 04−05, 2024, Berlin, Germany

GA²LEN Global Urticaria Forum (GUF)

December 07−09, 2023, São Paulo, Brazil

GA²LEN UCARE Conference 2023

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the phase 3 studies

Safety and efficacy of remibrutinib in Japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)

Physician’s perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the phase 3 REMIX-1 and REMIX-2 studies

CSU disease activity band shift after long-term treatment with remibrutinib in the phase 3 REMIX-1 and REMIX-2 studies

Frequency of angioedema in patients with chronic spontaneous urticaria: Report from the Urticaria Voices study

No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria

Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the phase 3 REMIX-1 and REMIX-2 studies

Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

REMIX-1/-2: Early symptom improvements with remibrutinib in chronic spontaneous urticaria from week 1

Efficacy of remibrutinib on patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies

Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the phase 3 REMIX-1 and REMIX-2 studies

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study

Efficacy and safety of remibrutinib in CSU: REMIX 1&2 Studies

Long-term safety and efficacy of remibrutinib in patients with CSU

Remibrutinib improves hive severity in patients with CSU

Study design of remibrutinib Phase-3b extension trial in CSU patients

Remibrutinib achieves early and high response rates in CSU patients

Remibrutinib provides fast, clinically important improvement of CSU disease activity

Remibrutinib showed good stability of response in patients with CSU

Remibrutinib improves itch, sleep and activity in patients with CSU

Remibrutinib showed no impact on blood counts in CSU patients

Remibrutinib showed no impact on serum immunoglobulin in CSU patients

Remibrutinib improves CSU symptoms irrespective of previous anti-IgE treatment

Pooled safety analysis of remibrutinib in inflammatory immune-mediated diseases

Remibrutinib improves CSU in patients regardless of prior oral treatments

Systemic manifestations during symptomatic episodes in CSU: Urticaria Voices Study

Urticaria Voices: Patient-reported outcome measures for monitoring CSU in clinic

Antihistamine treatment patterns and patient reported control In CSU

Patients’ perspective on negative impact of CSU on their lives

Remission and relapse profiles in chronic urticaria: PREDICT-CU study

December 04−05, 2024, Berlin, Germany

GA2LEN Global Urticaria Forum (GUF)

December 07−09, 2023, São Paulo, Brazil

GA2LEN UCARE Conference 2023

Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the phase 3 studies

Safety and efficacy of remibrutinib in Japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)

Physician’s perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the phase 3 REMIX-1 and REMIX-2 studies

CSU disease activity band shift after long-term treatment with remibrutinib in the phase 3 REMIX-1 and REMIX-2 studies

Frequency of angioedema in patients with chronic spontaneous urticaria: Report from the Urticaria Voices study

No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria

Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the phase 3 REMIX-1 and REMIX-2 studies

Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies

REMIX-1/-2: Early symptom improvements with remibrutinib in chronic spontaneous urticaria from week 1

Efficacy of remibrutinib on patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies

Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the phase 3 REMIX-1 and REMIX-2 studies

Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study

Efficacy and safety of remibrutinib in CSU: REMIX 1&2 Studies

Long-term safety and efficacy of remibrutinib in patients with CSU

Remibrutinib improves hive severity in patients with CSU

Study design of remibrutinib Phase-3b extension trial in CSU patients

Remibrutinib achieves early and high response rates in CSU patients

Remibrutinib provides fast, clinically important improvement of CSU disease activity

Remibrutinib showed good stability of response in patients with CSU

Remibrutinib improves itch, sleep and activity in patients with CSU

Remibrutinib showed no impact on blood counts in CSU patients

Remibrutinib showed no impact on serum immunoglobulin in CSU patients

Remibrutinib improves CSU symptoms irrespective of previous anti-IgE treatment

Pooled safety analysis of remibrutinib in inflammatory immune-mediated diseases

Remibrutinib improves CSU in patients regardless of prior oral treatments

Systemic manifestations during symptomatic episodes in CSU: Urticaria Voices Study

Urticaria Voices: Patient-reported outcome measures for monitoring CSU in clinic

Antihistamine treatment patterns and patient reported control In CSU

Patients’ perspective on negative impact of CSU on their lives

Remission and relapse profiles in chronic urticaria: PREDICT-CU study

GA²LEN Global Urticaria Forum (GUF)

GA²LEN UCARE Conference 2023